![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology](https://www.thelancet.com/cms/attachment/920222f6-291f-43c1-bae7-36f1bc4968b9/gr1.jpg)
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? | BMC Medicine | Full Text Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? | BMC Medicine | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12916-015-0472-7/MediaObjects/12916_2015_472_Fig1_HTML.gif)
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? | BMC Medicine | Full Text
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/cci/2019/cci.2019.3/cci.19.00013/20190809/images/large/cci.19.00013t1.jpeg)
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
![Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070346/F2.large.jpg)
Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis | The BMJ
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)